These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 16171734)

  • 21. Bleeding patterns of adolescents using a combination contraceptive injection for 1 year.
    Bortolotti de Mello Jacobucci MS; Guazzelli CA; Barbieri M; Araújo FF; Moron AF
    Contraception; 2006 Jun; 73(6):594-7. PubMed ID: 16730490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pseudocyesis in a teenager using long-term contraception.
    Ayakannu T; Wordsworth S; Smith R; Raghunandan R; Vine S
    J Obstet Gynaecol; 2007 Apr; 27(3):322-3. PubMed ID: 17464828
    [No Abstract]   [Full Text] [Related]  

  • 23. Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen.
    Coffee AL; Sulak PJ; Kuehl TJ
    Contraception; 2007 Jun; 75(6):444-9. PubMed ID: 17519150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives.
    Kearney BP; Mathias A
    Pharmacotherapy; 2009 Aug; 29(8):924-9. PubMed ID: 19637945
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J; Zhu Y; Jiang Y; Cao Y
    Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 microg and ethinylestradiol 15 microg (Minesse).
    Barbosa IC; Filho CI; Faggion D; Baracat EC
    Contraception; 2006 Jan; 73(1):30-3. PubMed ID: 16371291
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pituitary-ovarian hormone levels and symptoms in oral contraceptive users: comparison of a 21/7-day and extended regimen.
    Kuehl TJ; Speikermann AM; Willis SA; Coffee A; Sulak PJ
    J Reprod Med; 2008 Apr; 53(4):266-70. PubMed ID: 18472649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Acceptance of the paper pill as a method of regulating fertility].
    Reynoso L; Rosas D; Muñóz MC; Sánchez RA; Aznar R
    Ginecol Obstet Mex; 1980 Apr; 47(282):261-7. PubMed ID: 7390220
    [No Abstract]   [Full Text] [Related]  

  • 29. Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on thyroid hormones and androgen parameters: conventional vs. extended-cycle use.
    Sänger N; Stahlberg S; Manthey T; Mittmann K; Mellinger U; Lange E; Kuhl H; Wiegratz I
    Contraception; 2008 Jun; 77(6):420-5. PubMed ID: 18477491
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined estradiol/gestodene and acute pancreatitis.
    Trenque-Tessereau MG; Picot C; Herment N; Trenque TC
    Ann Pharmacother; 2005 Nov; 39(11):1953-4. PubMed ID: 16204389
    [No Abstract]   [Full Text] [Related]  

  • 31. Transdermal hormonal contraception: benefits and risks.
    Burkman RT
    Am J Obstet Gynecol; 2007 Aug; 197(2):134.e1-6. PubMed ID: 17689623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extended- and continuous-cycle oral contraceptives.
    Shrader SP; Dickerson LM
    Pharmacotherapy; 2008 Aug; 28(8):1033-40. PubMed ID: 18657019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of taranabant, an orally active, highly selective, potent cannabinoid-1 receptor (CB1R) inverse agonist, on ethinyl estradiol and norelgestromin plasma pharmacokinetics.
    Schwartz JI; Dunbar S; Yuan J; Li S; Miller DL; Rosko K; Johnson-Levonas AO; Lasseter KC; Wagner JA
    J Clin Pharmacol; 2009 Jan; 49(1):72-9. PubMed ID: 18936284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extended cycling of combined hormonal contraceptives in adolescents: physician views and prescribing practices.
    Gerschultz KL; Sucato GS; Hennon TR; Murray PJ; Gold MA
    J Adolesc Health; 2007 Feb; 40(2):151-7. PubMed ID: 17259055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Ectopia of cervix of the uterus and hormonal contraception].
    Jangidze M; Museridze N; Zakaraia L
    Georgian Med News; 2006 Dec; (141):21-6. PubMed ID: 17261880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial.
    Johnson JV; Lowell J; Badger GJ; Rosing J; Tchaikovski S; Cushman M
    Obstet Gynecol; 2008 Feb; 111(2 Pt 1):278-84. PubMed ID: 18238963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The contraceptive vaginal ring compared with the combined oral contraceptive pill: a comprehensive review of randomized controlled trials.
    Roumen FJ
    Contraception; 2007 Jun; 75(6):420-9. PubMed ID: 17519147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors associated with willingness to use the contraceptive vaginal ring.
    Gilliam M; Holmquist S; Berlin A
    Contraception; 2007 Jul; 76(1):30-4. PubMed ID: 17586133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endometrial effects of a 91-day extended-regimen oral contraceptive with low-dose estrogen in place of placebo.
    Anderson FD; Feldman R; Reape KZ
    Contraception; 2008 Feb; 77(2):91-6. PubMed ID: 18226671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.